Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D

被引：3

作者：

Kim, R. ^{[1
]}

Chaves, J. ^{[2
]}

Kavan, P. ^{[3
]}

Fakih, M. ^{[4
]}

Kortmansky, J. S. ^{[5
]}

Spencer, K. ^{[6
]}

Wong, L. ^{[7
]}

Tehfe, M. ^{[8
]}

Li, J. J. ^{[9
]}

Eyring, A. D. ^{[9
]}

Mayo, C. ^{[9
]}

Chiorean, E. G. ^{[10
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, GI Oncol, Tampa, FL USA

[2] Northwest Med Specialties LLC, Hematol Oncol, Tacoma, WA USA

[3] Jewish Gen Hosp, Oncol, Montreal, PQ, Canada

[4] City Hope Comprehens Canc Ctr, Med Oncol & Therapeut Res, Duarte, CA USA

[5] Yale Canc Ctr, Med, New Haven, CT USA

[6] Rutgers Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA

[7] Baylor Scott & White Hlth, Hematol Oncol, Temple, TX USA

[8] Ctr Hosp Univ Montreal, Med Hematol Oncol, Montreal, PQ, Canada

[9] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[10] Univ Washington, Med, Seattle, WA 98195 USA

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493P

引用

页码：S450 / S450

页数：1